Role of systems pharmacology in understanding drug adverse events

Wiley Interdisciplinary Reviews: Systems Biology and Medicine

Volumn 3, Issue 2, 2011, Pages 129-135

  Berger, Seth I ^a   Iyengar, Ravi ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

DRUG DELIVERY SYSTEM; HUMAN; PHARMACOLOGY; REVIEW; SYSTEMS BIOLOGY;

DRUG DELIVERY SYSTEMS; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOLOGY; SYSTEMS BIOLOGY;

EID: 79957936421     PISSN: 19395094     EISSN: 1939005X     Source Type: Journal    
DOI: 10.1002/wsbm.114     Document Type: Article

References (31)

1. Berger SI, Iyengar R. Network analyses in systems pharmacology. Bioinformatics 2009, 25:2466-2472.
2. Wist AD, Berger SI, Iyengar R. Systems pharmacology and genome medicine: a future perspective. Genome Med 2009, 1:11.
3. Boran AD, Iyengar R. Systems pharmacology. Mt Sinai J Med 2010, 77(4):333-44.
4. Boran AD, Iyengar R. Systems approaches to polypharmacology and drug discovery. Curr Opin Drug Discov Devel 2010, 13(3):297-309.
5. Ma'ayan A, Jenkins SL, Goldfarb J, and Iyengar R. Network analysis of FDA approved drugs and their targets. Mt Sinai J Med 2007, 74:27-32.
6. Aronow WS. Treating hypertension in older adults: safety considerations. Drug Saf 2009, 32:111-118.
7. Kamali F. Genetic influences on the response to warfarin. Curr Opin Hematol 2006, 13:357-361.
8. Becquemont L. Pharmacogenomics of adverse drug reactions: practical applications and perspectives. Pharmacogenomics 2009, 10:961-969.
9. Holzer P. Opioid receptors in the gastrointestinal tract. Regul Pept 2009, 155:11-17.
10. Botchkarev VA. Molecular mechanisms of chemotherapy-induced hair loss. J Investig Dermatol Symp Proc 2003, 8:72-75.
11. Sica DA, Brath L. Angiotensin-converting enzyme inhibition-emerging pulmonary issues relating to cough. Congest Heart Fail 2006, 12:223-226.
12. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med 1992, 117:234-242.
13. Cheung BM. Therapeutic potential of angiotensin receptor blockers in hypertension. Expert Opin Investig Drugs 2006, 15:625-635.
14. Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, Hufeisen SJ, Jensen NH, Kuijer MB, Matos RC, Tran TB, Whaley R, Glennon RA, Hert J, Thomas KL, Edwards DD, Shoichet BK, Roth BL. Predicting new molecular targets for known drugs. Nature 2009, 462:175-181.
15. Joshi A, Dimino T, Vohra Y, Cui C, Yan GX. Preclinical strategies to assess QT liability and torsadogenic potential of new drugs: the role of experimental models. J Electrocardiol 2004, 37(suppl):7-14.
16. Tesfa D, Keisu M, Palmblad J. Idiosyncratic drug-induced agranulocytosis: possible mechanisms and management. Am J Hematol 2009, 84:428-434.
17. Kuhn M, Campillos M, González P, Jensen LJ, Bork P. Large-scale prediction of drug-target relationships. FEBS Lett 2008, 582:1283-1290.
18. Günther S, Kuhn M, Dunkel M, Campillos M, Senger C, Petsalaki E, Ahmed J, Urdiales EG, Gewiess A, Jensen LJ, Schneider R, Skoblo R, Russell RB, Bourne PE, Bork P, Preissner R. SuperTarget and Matador: resources for exploring drug-target relationships. Nucleic Acids Res 2008, 36(Database issue):D919-D922.
19. Xie L, Li J, Bourne PE. Drug discovery using chemical systems biology: identification of the protein-ligand binding network to explain the side effects of CETP inhibitors. PLoS Comput Biol 2009, 5:e1000387.
20. Yang L, Chen J, He L. Harvesting candidate genes responsible for serious adverse drug reactions from a chemical-protein interactome. PLoS Comput Biol 2009, 5:e1000441.
21. Yang L, Luo H, Chen J, Xing Q, He L. SePreSA: a server for the prediction of populations susceptible to serious adverse drug reactions implementing the methodology of a chemical-protein interactome. Nucleic Acids Res 2009, 37(Web Server issue):W406-W412.
22. Yang L, Xu L, He L. A CitationRank algorithm inheriting Google technology designed to highlight genes responsible for serious adverse drug reaction. Bioinformatics 2009, 25:2244-2250.
23. Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P. Drug target identification using side-effect similarity. Science 2008, 321:263-266.
24. Hoffmann P, Warner B. Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends. J Pharmacol Toxicol Methods 2006, 53:87-105.
25. Alberghina L, Hofer T, Vanoni M. Molecular networks and system-level properties. J Biotechnol 2009, 144:224-233.
26. Cosgrove BD, Alexopoulos LG, Saez-Rodriguez J, Griffith LG, Lauffenburger DA. A multipathway phospho-proteomic signaling network model of idiosyncratic drug-and inflammatory cytokine-induced toxicity in human hepatocytes. Conf Proc IEEE Eng Med Biol Soc 2009, 1:5452-5455.
27. Cosgrove BD, King BM, Hasan MA, Alexopoulos LG, Farazi PA, Hendriks BS, Griffith LG, Sorger PK, Tidor B, Xu JJ, Lauffenburger DA. Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity. Toxicol Appl Pharmacol 2009, 237:317-330.
28. Wagner BK, Kitami T, Gilbert TJ, Peck D, Ramanathan A, Schreiber SL, Golub TR, Mootha VK. Large-scale chemical dissection of mitochondrial function. Nat Biotechnol 2008, 26:343-351.
29. Scheiber J, Jenkins JL, Sukuru SC, Bender A, Mikhailov D, Milik M, Azzaoui K, Whitebread S, Hamon J, Urban L, Glick M, Davies JW. Mapping adverse drug reactions in chemical space. J Med Chem 2009, 52:3103-3107.
30. Berger SI, Ma'ayan A, Iyengar R. Systems pharmacology of arrhythmias. Sci Signal 2010, 3:ra30.
31. Csoka AB, Szyf M. Epigenetic side-effects of common pharmaceuticals: a potential new field in medicine and pharmacology. Med Hypotheses 2009, 73:770-780.